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ABSTRACT
ABCA1, a member of the ATP-binding cassette family of
transporters, lipidates ApoE (apolipoprotein A) and is
essential for the generation of HDL (high-density lipopro-
tein)-like particles in the CNS (central nervous system). Lack
of Abca1 increases amyloid deposition in several AD
(Alzheimer’s disease) mouse models. We hypothesized that
deletion of only one copy of Abca1 in APP23 (where APP is
amyloid precursor protein) AD model mice will aggravate
memory deficits in these mice. Using the Morris Water
Maze, we demonstrate that 2-year-old Abca1 heterozygous
APP23 mice (referred to as APP23/het) have impaired
learning during acquisition, and impaired memory reten-
tion during the probe trial when compared with age-
matched wild-type mice (referred to as APP23/wt). As in
our previous studies, the levels of ApoE in APP23/het mice
were decreased, but the differences in the levels of Ab and
thioflavin-S-positive plaques between both groups were
insignificant. Importantly, dot blot analysis demonstrated
that APP23/het mice have a significantly higher level of
soluble A11-positive Ab (amyloid b protein) oligomers
compared with APP23/wt which correlated negatively with
cognitive performance. To confirm this finding, we
performed immunohistochemistry with the A11 antibody,
which revealed a significant increase of A11-positive
oligomer structures in the CA1 region of hippocampi of
APP23/het. This characteristic region-specific pattern of
A11 staining was age-dependent and was missing in
younger APP23 mice lacking Abca1. In contrast, the levels
of Ab*56, as well as other low-molecular-mass Ab
oligomers, were unchanged among the groups. Overall,
the results of the present study demonstrate that in aged
APP23 mice memory deficits depend on Abca1 and are
likely to be mediated by the amount of Ab oligomers
deposited in the hippocampus.
Key words: ABCA1, Abca1-knockout mouse, Alzheimer’s
disease, amyloid b protein, apolipoprotein E (ApoE), APP
transgenic mouse.
INTRODUCTION
AD (Alzheimer’s disease) is senile dementia characterized by
extracellular amyloid plaques and intracellular neurofibrillary
tangles. Amyloid plaques comprising fibrillar Ab (amyloid b
protein) are thought to be central to AD pathogenesis.
Previously, three different groups have reported that global
deletion of Abca1 (ATP-binding cassette transporter 1), in AD
model mice [APP (amyloid precursor protein) transgenic mice]
increased the level of Ab plaques in the brain; however,
cognitive function was not examined (Hirsch-Reinshagen et
al., 2005; Koldamova et al., 2005a; Wahrle et al., 2005).
ABCA1 exports cholesterol and phospholipids from cells on to
lipid-poor apolipoproteins (ApoA-I, ApoE and others) and
forms nascent HDL (high-density lipoprotein) particles. The
transcriptional activation of ABCA1 and APOE (in both
humans and mice) is controlled by nuclear LXRs (liver X
receptors) a and b (LXRa/b) (Tontonoz and Mangelsdorf,
2003), and our previous studies have demonstrated that the
effect of LXRs on soluble Ab is mediated through ABCA1
(Tontonoz and Mangelsdorf, 2003; Koldamova et al., 2005b;
Koldamova and Lefterov, 2007). Mutations in human ABCA1
cause severe HDL deficiencies, the most prominent of which is
Tangier disease, characterized by the virtual absence of ApoA-
I and HDL, accumulation of cholesterol in cells and prevalent
atherosclerosis (Oram and Heinecke, 2005). ABCA1 also has an
important role in the CNS (central nervous system); it is
responsible for the lipidation of ApoE and the formation of
HDL-like lipoproteins, which transport cholesterol in the
brain. Studies have shown that the lack of Abca1 in mice
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asnneuro.org / Volume 1 (2) / art:e00006 65greatly reduces the levels of ApoE, probably caused by an
increased degradation of abnormally lipidated ApoE (Hirsch-
Reinshagen et al., 2004; Wahrle et al., 2004). It has been
reported that the elevation in amyloid plaque load in APP/
Abca1
ko mice is accompianed by a dramatic decrease in
soluble ApoE, with no change in insoluble ApoE (Hirsch-
Reinshagen et al., 2005; Koldamova et al., 2005a; Wahrle et
al., 2005). In contrast, the overexpression of Abca1 in PDAPP
[PDGF (platelet-derived growth factor) APP] mice resulted in
less amyloid plaques than in PDAPP mice expressing a normal
level of Abca1 (Wahrle et al., 2008).
In the present paper we report the effects of Abca1 on
spatial learning and memory retention in APP transgenic mice
(the APP23 line), by comparing cognitive performance of 22–
24-month-old APP23 mice with one or two copies of the
Abca1 gene using the MWM (Morris Water Maze) paradigm.
We chose to examine Abca1 heterozygous mice instead of
Abca1 knockout mice because the global deletion of Abca1 (in
Abca1 knockout mice) or two non-functional copies of ABCA1
(as in Tangier disease) should be considered an extreme
example. Reduced ABCA1 transport function due to genetic
variants, rather than complete loss of the transporter, is
common in the human population and is often accompanied
by distinct clinical phenotypes (Oram and Heinecke, 2005).
Previous studies have shown that APP23 mice display memory
deficits demonstrated by impaired learning during acquisition
in the MWM, although the performance during the probe trial
was not impaired in all studies (Kelly et al., 2003; Van Dam et
al., 2003, 2005). Our results demonstrate that the lack of only
one copy of Abca1 impaired spatial learning in APP23 mice.
Surprisingly, the memory deficits in APP23/Abca1 heterozyg-
ous mice did not correlate with amyloid load, but to the level
of soluble Ab oligomers in their brain.
MATERIALS AND METHODS
Transgenic mice
All animal experiments were approved by the University of
Pittsburgh Institutional Animal Care and Use Committee. Two
well-characterized model mouse lines were used to set up
breeding pairs and to generate experimental groups. APP23
transgenic mice express the human familial AD mutant
APP751 with Swedish double mutations at positions 670/671
(APPK670N, M671L) (Sturchler-Pierrat et al., 1997). The
expression of human APPsw is driven by the murine Thy-1
promoter and is restricted to neurons. Abca1
+/2 heterozygous
mice, originally generated by McNeish et al. (2000) at Pfizer,
were obtained from Jackson Laboratories, line DBA/
1-Abca1
tm1Jdm/J. Abca1
+/2 mice were crossed to APP23 mice
(C57BL/6 background) to generate the APP23/Abca1
+/2
(APP23/het) progeny. The progeny were identified by PCR
and APP23/het mice were bred to Abca1
+/2 littermates to
yield APP23/Abca1
+/2 (APP23/het) and APP23/Abca1
+/+
(APP23/wt) bigenic littermate mice (Koldamova et al.,
2005a). Thus all APP23/het and APP23/wt mice used in the
present study are hemizygous APP23. APP23/het developed
similarly to APP23/wt and no gross anatomical abnormalities
were observed until 24 months of age. For the purpose of the
present study we used mice of two ages with the following
genotypes: APP23/het (ten females and three males), APP23/
wt (13 females and four males), both groups at 22–24 months
of age, and APP23/wt or APP23/Abca1
2/2 (APP23/ko) mice at
13 months of age. In addition, for behavioural tests we used
22–24-month-old wild-type (wt/wt) mice and mice with one
copy of a functional Abca1 gene (Abca1
+/2 referred to as wt/
het) as APP non-transgenic littermate controls.
MWM
A modified version of the MWM was used to assess spatial
navigation learning and memory retention. The water maze
studies were conducted in the Rodent Behavior Analysis Core
of the University of Pittsburgh Health Sciences Department.
In a circular pool of water (diameter 100 cm, height 30 cm,
temperature 25¡1˚C) we measured the ability of mice to
form a representation of the spatial relationship between a
safe, but invisible (submerged 1 cm below the water level),
platform (10 cm in diameter), and visual cues surrounding the
pool of water. The platform was located in the centre of one
of the four quadrants of the pool. Several extra maze cues
were distributed across the walls surrounding the pool.
Animals received two habituation trials (one per day) during
which the animals were handled for several minutes by the
experimenter and allowed to explore the pool of water
without the platform present. Beginning the next day, they
received four daily hidden platform training (acquisition)
trials with 10–12 min inter-trial intervals for four consecutive
days. Animals were allowed 60 s to locate the platform and
40 s to rest on it. Mice that failed to find the platform were
placed on the platform by the experimenter and allowed to
rest there for 40 s. At 24 h following the last acquisition trial,
a single 60 s probe trial was administered to assess spatial
memory retention. For the probe trial, animals were returned
to the maze as during training, but with no platform present.
Performance was recorded with an automated tracking
system (SMART; San Diego Instruments) during all training
and probe trials. During the acquisition trials, latency to reach
the platform and path length (distance swum to the
platform) were subsequently used to analyse and compare
the performance between different groups of mice. The
relative time spent in each of the four quadrants and the
number of crossings of the former platform location were
recorded and analysed during the probe trials.
Animal tissue processing
Mice were anaesthetized with Avertin (250 mg/kg of body
weight, intraperitoneal injection; Sigma) and perfused
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rapidly removed, divided into hemispheres, and the olfactory
bulbs and cerebellum were removed. One hemisphere was
snap-frozen on dry ice and the other was drop fixed in 4%
phosphate-buffered paraformaldehyde at 4˚C for 48 h before
being stored in 30% sucrose.
Histology and immunohistochemistry
All procedures were as reported previously (Koldamova et al.,
2005a) with the following modifications. Histoprep (Fisher
Scientific)-embedded hemibrains were cut in the coronal plane
at 30 mm sections on a cryostat and stored in a glycol-based
cryoprotectant at 220˚C until immunostained. Sections were
selected 700 mm apart, starting from a randomly chosen
section approx. 150 mm caudal to the first appearance of the
CA3 and dentate gyrus. Sections were mounted on Superfrost
Plus slides (Fisher Scientific) and outlined with a delimiting pen
(DakoCytomation). After sections were washed in PBST (PBS
containing 0.2% Triton X-100), non-specific binding was
blocked by incubating the sections for 1 h in PBST with 3%
normal goat serum (Sigma). Sections were incubated either
overnight at 4˚C or for 3 h at room temperature (22˚C) with
one of the following antibodies: polyclonal rabbit anti-GFAP
(glial fibrillary acidic protein) antibody (1:1000;
DakoCytomation) or polyclonal rabbit anti-oligomer antibody
(A11; 1:600; Invitrogen). The anti-GFAP antibody recognizes
the principal intermediate filament of mature astrocytes and
A11 recognizes a peptide backbone epitope common to
amyloid oligomers, but not found in native proteins,
amyloidogenic monomer or mature amyloid fibrils. Sections
were washed in PBST and incubated at room temperature for
1 h in the corresponding secondary antibody: Alexa FluorH
546-conjugated goat anti-mouse IgG (1:1000; Molecular
Probes) or Texas Red-conjugated goat anti-rabbit IgG
(1:1000, Molecular Probes). The specificity of the staining was
confirmed by the lack of signal when applying the same
protocol on brain sections from non-transgenic wild-type mice.
For Thio-S (thioflavine S) staining, mounted sections were
processed essentially as previously described (Koldamova et al.,
2005a). Sections mounted on Superfrost Plus slides were post-
fixed in 10% formalin for 10 min, washed in PBS, incubated in
0.25% potassium permanganate for 10 min, bleached in a
solutioncontaining2%potassiummetabisulfateand1%oxalic
acid until they appeared white, and finally stained for 10 min
in 0.015% Thio-S in 50% ethanol. After washing in 50%
ethanol and water, the slides were dried before being
coverslipped with Fluoromount-G (Southern Biotech).
X-34 [1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-ben-
zene] is a highly fluorescent derivative of Congo Red that
can be used to detect senile plaques and was provided by Dr
W. Klunk (Department of Psychiatry, University of Pittsburgh,
Pittsburgh, PA, U.S.A.). X-34 staining was performed on
mounted sections as described previously (Ikonomovic et al.,
2006). Briefly, sections mounted on Superfrost Plus slides
were post-fixed in 10% formalin for 10 min, washed in PBS
for 5 min and stained with X-34 (100 mM) for 10 min.
Following the staining, sections were washed in distilled
water, incubated in 0.2% NaOH in 80% unbuffered ethanol,
washed again, and soaked for 10 min in distilled water. Slides
were dried and coverslipped with Fluoromount-G/DAPI (49,6-
diamidino-2-phenylindole) nuclear stain.
Microscopic examination was carried out using a Nikon
Eclipse 80i microscope and images were captured by a
Nikon DS Qi1MC camera. For quantitative analysis, immuno-
staining in the neocortex and hippocampus was defined as
the percentage area covered by immunoreactivity, Thio-S or
X-34 positivity. The percentage of immunoreactivity and
positivity was determined by examining the entire area of
interest for each section using Nikon Elements v3.0 software.
Confocal microscopy was performed on an Olympus Fluoview
1000 inverted confocal microscope.
Ab ELISA and Western blot analysis
Ab ELISA and Western blot analysis were performed
essentially as described in Koldamova et al. (2005a). The
frozen hemibrains (only cortices and hippocampi) were
homogenized in THB [tissue homogenization buffer; 250
mM sucrose, 20 mM Tris base, 1 mM EDTA, 1 mM EGTA (pH
7.3), 1 ml per 150 mg of tissue) and protease inhibitors {10
mg/ml leupeptin, 10 mg/ml aprotinin and 10 mg/ml AEBSF [4-
(2-aminoethyl)benzenesulfonyl fluoride]}. Protein extracts
were prepared by a 1:1 dilution of the initial homogenate
with 26RIPA {10 mM Tris/HCl (pH 7.3), 1 mM MgCl2, 0.25%
SDS and 1% Triton X-100 in the presence of protease
inhibitors [10 mg/ml leupeptin, 10 mg/ml aprotinin and 10 mg/
ml 4-(2-aminoethyl)benzenesulfonyl hydrochloride]} buffer
in the presence of protease inhibitors and Western blot
analysis for Abca1, ApoE and APPfl were performed as
previously described (Koldamova et al., 2005a). To examine Ab
oligomers on Western blotting, the proteins were resolved on
4–12% Bis-Tris gels (Invitrogen) and probed with the 6E10
antibody. Extraction of soluble and insoluble Ab was carried
out as described in Koldamova et al. (2005a). An ELISA for Ab
was performed using 6E10 as the capture antibody, and anti-
Ab40 (G2-10 mAb) and anti-Ab42 (G2-13 mAb) monoclonal
antibodies conjugated to horseradish peroxidase (Genetics
Company) were used as the detection antibodies. The final
values of Ab were based on Ab-(1–40) and Ab-(1–42) peptide
standards (Bachem Biosciences) and normalized amounts of
Ab were expressed as pmol/mg of protein.
Brain soluble Ab oligomer analysis
The level of soluble Ab oligomers was measured by dot blot
assay as described previously (Kayed et al., 2003, 2007) with
slight modification. Briefly, soluble amyloid peptide was
extracted in RIPA buffer containing protease inhibitors (see
above). After centrifugation at 100 000 g for 1 h at 4˚C, the
supernatant was analysed. Samples (1 mg) of total protein were
spotted on to nitrocellulose membrane and probed with the
A11 antibody (1:1000), specific for oligomeric forms of Ab. The
Abca1, Ab oligomers and learning in APP23 mice
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67immunoreactive signals were visualized using an ECL
(enhanced chemiluminescence) detection kit (GE Healthcare)
and were quantified densitometrically (Image Quant). The
exactsamesampleswerespottedontoadditionaldotblotsand
probed with 6E10 and Bradford reagent for normalization.
Statistical analysis
All results are reported as means¡S.E.M. Statistical signifi-
cance for ELISA, Western blotting and dot blotting data was
determined using a two-tailed Student’s t test. Significant
differencesbetweenmeanscoresduringacquisitiontrialblocks
in the MWM were assessed with two-way repeated measures
ANOVA (General Linear Model/RM-ANOVA) with Tukey’s post-
hoc analysis for multiple comparisons using genotype and trial
block number as sources of variation. A two-tailed Student’s t
test was used to evaluate the difference between the number
of crossings through the platform location during the probe
trial. Comparisons of percentage immunoreactivity between
ages and genotypes were performed using one-way ANOVA
with Tukey’s post-hoc analysis. To determine a correlation
between variables the data were analysed by scatter plot and
by Pearson correlation analysis. Significance was defined as
P#0.05. All statistical analyses were performed in GraphPad
Prism, version 4.0 or SPSS, version 16, release 200.
RESULTS
Abca1 deficiency exacerbates cognitive
performance in APP23 mice
To assess Abca1 effects on cognitive performance we used the
MWM paradigm and tested spatial learning and memory
retention in 22–24-month-old APP23/het and APP23/wt
mice. Age-matched wt/wt and wt/het mice were used as APP
non-transgenic controls.
During the acquisition phase, as illustrated by the learning
curves in Figure 1, all groups improved their performance
with increased training. RM-ANOVA analysis revealed a
significant main effect of the trial block on both dependent
variables: distance swum to the platform or path length
(P,0.001) and escape latency (P,0.001). Between subjects,
the factor genotype had a significant effect only on the path
length (P,0.001), but not on the escape latency. One-way
ANOVA demonstrated a significant difference between the
groups (P,0.001) for path and escape latency (P,0.05) on
the last two trial days. APP23/wt learned significantly slower
than non-transgenic wt/wt mice (wt/wt compared with
APP23/wt: day 2 and 3, path length, P,0.05 and P,0.01;
day 3, escape latency, P,0.05), although their performance
ultimately reached control levels on the last day of the
training phase (Figures 1A and 1B). In contrast, APP23/het
never learned this task as efficiently as non-transgenic wt/het
mice. Most importantly, as visible from learning curves in
Figures 1(A) and 1(B), APP23/wt mice displayed better spatial
acquisition compared with APP23/het animals demonstrated
by the differences in both path length (Figure 1A; 235¡27
cm compared with 407¡45 cm, P,0.01) and escape latency
(Figure 1B; 19.88¡1.9 s compared with 28.98¡2.69 s;
P,0.01) on the last day of the training. No significant
differences were identified in the learning curves between
wt/het and wt/wt non-transgenic mice.
At 24 h after the last training session, mice were tested in a
probe trial during which search patterns were monitored in
the absence of a platform. As visible from Figure 1(C), APP23/
wt, as well as the non-transgenic controls, had normal spatial
memory retention. In contrast, APP23/het had significantly
fewer numbers of crossings over the original target location
Figure 1 Abca1 deficiency exacerbates cognitive deterioration in APP23 mice: MWM tests
(A) Mean distance swum to the platform (path lengths) represents the average distance to find the platform. P,0.001 for trial days
2, 3 and 4 (as measured by one-way ANOVA analyses). (B) Escape latency scores represent average acquisition time taken to find the
platform, per trial block. P,0.05 for trial days 3 and 4 (as measured by one-way ANOVA). In (A) and (B), *P,0.05 APP23/het compared
with APP23/wt; +P,0.05 and ++P,0.01 APP23/wt compared with wt/wt (as measured using a Tukey’s post-hoc test). (C) Probe trial.
Platform crossingsarecalculatedasthenumberofcrossesovertheexactlocationofthehiddenplatform.*P,0.05APP23/hetcompared
with APP23/wt (as measured by two-tailed Student’s t test analysis). All values represent means¡S.E.M. All mice tested were between
22 and 24 months of age. APP23/wt n517, APP23/het n513, wt/wt n513 and wt/het n54 mice per group.
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(Figure 1C; 2.1 compared with 1.2, P,0.05). The difference in
performance at any test point could not be attributed to
lower swimming velocity of the APP23/het mice, as two-way
RM-ANOVA revealed no significant difference among the
groups (P.0.1 in all comparisons; results not shown). Our
conclusion is that Abca1 deficiency exacerbates spatial
memory in APP23 mice, exemplified by worsened cognitive
performance during both the acquisition and retention
phases of MWM paradigm.
Cognitive decline in APP23/het mice does not
correlate with the level of insoluble amyloid in
their brain
Previous work from our group and others have demonstrated
that the lack of Abca1 significantly affects both brain ApoE
protein levels and its degradation, and increases amyloid
deposition in APP transgenic mice (Hirsch-Reinshagen et al.,
2005; Koldamova et al., 2005a; Wahrle et al., 2005). Similarly
to our previous studies (Koldamova et al., 2005a) we found
that the level of soluble ApoE in the brains of APP23/wt mice
with two intact copies of Abca1 was significantly higher than
in APP23/het animals (Figure 2A, P,0.05). In terms of
amyloid phenotype, the level of soluble Ab40 (RIPA
extraction) was decreased and that of Ab42 was unchanged
(Figure 2B). Corresponding to the decreased soluble Ab40,
APP23/het had significantly more Ab40 in the insoluble brain
fraction (formic acid extraction), compared with APP23/wt,
whereas the levels of insoluble Ab42 did not differ
(Figure 2C). To determine the relationship between the level
of insoluble Ab40 and Ab42, and the performance in the
MWM, we performed a correlation analysis. Scatter plots
shown in Figures 2(D) and 2(E) demonstrate that there was no
correlation between the number of crossings over the target
platform and Ab40 (P50.51) or Ab42 (P50.82).
To determine how the amyloid pathology corresponds to
the memory deficits in mice subjected to behavioural testing,
the amount of Ab deposited into plaques was also examined
Figure 2 The level of insoluble Ab does not correlate with the cognitive deficits in APP23/het and APP23/wt mice
(A) Soluble ApoE was extracted from cortices and hippocampi using DEA and the level was determined by Western blot analysis. (B
and C)A b was sequentially extracted from cortices and hippocampi of 24-month-old APP23/wt and APP23/het mice first using RIPA
(soluble fraction) followed by formic acid (insoluble fraction) and Ab40 and Ab42 was measured by ELISA. Assessment of (B) soluble
Ab and (C) insoluble Ab.* P,0.05 and **P, 0.01 (as measured using a two-tailed Student’s t test). (D and E) Relationship between
probe trial performance in MWM and levels of insoluble Ab40 (D) and Ab42 (E) in 24-month-old APP23/wt and APP23/het. Levels
of insoluble Ab in individual mice were normalized to the average levels in APP23/wt mice. Note that there was no correlation
between insoluble Ab40 and Ab42 and the numbers of target crossings during the probe trial. n513–16 per group.
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69using immunohistochemistry. Brain sections were stained
with Thio-S for detection of compact parenchymal Ab
deposits and cerebral amyloid angiopathy (Figures 3A and
3B). Parametric ANOVA revealed no significant effect of
Abca1 genotype. Similarly, there was no significant differ-
ence in the percentage of Thio-S-positive staining in the
hippocampus (P50.78). Reactive gliosis is a common feature
associated with various factors for AD, which may play a role
in the progression of AD. Senile plaques are surrounded by
high levels of reactive astrocytes producing pro-inflammatory
cytokines and reactive oxygen species, which exacerbate the
amyloid pathology and cognitive decline observed in APP
transgenic mice (Town et al., 2008; Zhou et al., 2008). To
determine the level of astrogliosis, brain sections from
APP23/wt and APP23/het mice were immunostained for
GFAP. Although high levels of GFAP-labelled astrocytes
surrounded Thio-S-positive plaques (Figure 3C), there was
no difference in GFAP immunostaining when comparing 24-
month-old APP23/wt and APP23/het mice. In addition, we
measured mRNA expression of a number of pro-inflammatory
cytokines [TNF-a (tumour necrosis factor-a), IL-6 (interleu-
kin-6), IL-1b and iNOS (inducible nitric oxide synthase)] using
our routine protocol for real-time quantitative PCR (Lefterov
et al., 2007), but did not find a difference between wild-type
(APP23/wt) and heterozygous (APP23/het) mice (results not
shown).
Cognitive decline in APP23/het mice correlates
with the level of soluble Ab oligomers in their
brains
Synaptic dysfunction caused by the accumulation of soluble
Ab oligomers (Kayed et al., 2003; Lesne et al., 2006; Shankar
et al., 2008) could be a possible explanation for the memory
impairment seen in APP23/het mice. We first examined the
level of Ab dodecameric (56 kDa) Ab42 assemblies (Ab*56),
recently suggested as a reason for memory deficits in APP-
expressing Tg2576 mice (Lesne et al., 2006). To determine
whether Ab*56 changes with aging we performed Western
blot analysis of RIPA-extracted brain proteins (cortex and
hippocampus) with the 6E10 antibody. The results demon-
strated that there was an age-dependent increase in the level
of the 56 kDa 12-mer Ab oligomer in APP23 mice making it a
potential marker for memory function in this AD mouse
Figure 3 Histological analysis of Thio-S-positive amyloid deposits in 24-month-old APP23 mice
(A) Brain sections from APP23/wt and APP23/het mice were stained with Thio-S to visualize fibrillar amyloid plaques. The
images represent the approximate average levels of Thio-S-positive plaques (206). (B) Graphical representation of the area of
the cortex and hippocampus covered by Thio-S-positive deposits. (C) Brain sections were immunostained with an anti-GFAP
antibody to show reactive astrogliosis and was co-stained with Thio-S for amyloid plaques (2006). n512 for APP23/wt and n511
for APP23/het.
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APP23/wt mice, there was a 6-fold increase of Ab*56 in 24-
month-old APP23/wt mice. However, there was no difference
in Ab*56 levels in 24-month-old APP23/wt and APP23/het
mice (Figure 4B) and no correlation with the performance in
the MWM. It has to be noted that there was variability in the
level of Ab*56 in the older group of mice illustrated by the
representative blot on Figure 4(B). Additional examination of
other Ab low-molecular-mass oligomer species detected at
molecular masses theoretically corresponding to trimeric (14
kDa), hexameric (27 kDa) and nonameric (40 kDa) Ab42
assemblies also did not show a significant difference between
APP23/wt and APP23/het groups (results not shown).
Next, we used the A11 anti-oligomeric antibody, which
was shown to detect higher-molecular-mass Ab oligomers on
dot and Western blotting (Kayed et al., 2003, 2007).
Figure 4(C) shows that, in APP23/wt mice at 13 months and
24 months, there is an age-dependent increase of Ab
oligomers recognized by A11 (P,0.05). Similar dot blot
analysis demonstrated that A11 immunoreactivity was
increased more than 2-fold in 24-month-old APP23/het mice
as compared with 24-month-old APP23/wt mice (Figure 4D;
P,0.01; upper panels of the inset are representative dot blots
with the A11 antibody). Previously it has been demonstrated
that, on a dot blot, 6E10 antibody detects Ab monomers and
Ab fibrils, but not prefibrillar oligomer Ab (Kayed et al., 2007;
Figure 4 The level of soluble Ab oligomers is increased in APP23/het mice
Ab was extracted with RIPA from cortices and hippocampi of 13-month-old APP23/wt, and 24-month-old APP23/wt and APP23/het
mice and Western and dot blot analyses were performed using 6E10 and A11 anti-oligomeric antibodies respectively. (A and B)
Comparison of 56 kDa Ab* in 13- and 24-month-old APP23/wt mice (A, n56 per group), and 24-month-old APP23/wt and APP23/het
(B, n513 per group) was performed using Western blot analysis with the 6E10 antibody (representative Western blots are shown
above the histograms). Note the variability in Ab*56 intensity in older mice. All Western blots were repeated three times. (C) Dot blot
assessment of Ab oligomers using the A11 antibody comparing samples from 13-month-old APP23/wt and 24-month-old APP23/wt
mice (n58). A representative dot blot is shown above the histogram. (D) Dot blot assessment of Ab oligomers using the A11 antibody
comparing samples from 24-month-old APP23/wt and APP23/het mice. The upper panel shows representative dot blots using the A11
antibody; the lower panel shows a representative dot blot using the same samples processed with the 6E10 antibody (n58). (E)
Western blot analysis of the Ab monomer in APP23/wt and APP23/het mice using the 6E10 antibody (n513). Values in (A–E)
represent means¡S.E.M. (F) Relationship between probe trial performance in MWM and levels of soluble A11-positive oligomers in
24-month-old mice. Scatter plot and Pearson correlation analysis were used to determine the relationship between the level of A11-
positive oligomers and performance at the probe trial. Note that there is a negative (Pearson r520.54), statistically significant,
correlation (P50.025) between the level of A11 oligomers and the number of crossings of the exact area of the target platform in
APP23/wt and APP23/het (n58–9 per group). For (A–F), the levels of 6E10- and A11-positive oligomers in individual mice were
normalized to the average levels in 24-month-old APP23/wt mice.
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71Necula et al., 2007). Therefore we also compared the samples
from 24-month-old APP23/het and APP23/wt mice perform-
ing dot blotting with 6E10 antibody. As shown in Figure 4(D)
there is no difference in 6E10 immunoreactivity on dot blots
from samples of 24-month-old APP23/het and APP23/wt
mice (Figure 4D; lower panels of the inset are representative
dot blots with 6E10). This confirms the results from ELISA and
Thio-S staining, that there is no difference in the fibrillar
amyloid among APP23/wt and APP23/het mice (see also
Figures 2C, 3A and 3B). To prove that the amount of protein
loaded on to the dots was equal, they were pre-stained with
Bradford reagent (results not shown). We also found that, in
accordance with the increased level of Ab oligomers in
APP23/het mice, there was a statistically significant decrease
in the level of Ab monomers in these mice when compared
with APP23/wt (Figure 4E; P,0.05). To determine the
relationship between the level of A11-positive oligomers
and performance in the MWM, the data were analysed by
correlation analysis. The scatter plot shown in Figure 4(F)
demonstrates that there was a negative (r520.54) and
statistically significant (P50.025) correlation between the
level of A11 oligomers and the number of crossings over the
target platform in wild-type and heterozygous APP23 mice
during the probe trial.
Increased A11 immunoreactivity in the CA1
region of the hippocampus of 24-month-old
APP23/het compared with APP23/wt mice
To confirm the preceding finding using a different method,
we performed immunohistochemistry with the A11 antibody
on sections from cortices and hippocampi. We compared the
following groups of mice: 13-month-old APP23/wt and
APP23/ko, and 24-month-old APP23/wt and APP23/het. We
specifically chose APP23/ko mice instead of APP23/het in the
younger group because our previous results did not show any
significant difference between Ab load in APP23/wt and
APP23/het at 13 months of age (Koldamova et al., 2005a). We
examined different regions of the hippocampus: CA1, CA2
and septum. As shown in Figure 5(A), when compared with
other groups, 24-month-old APP23/het demonstrated a
striking increase of A11 immunoreactivity in the CA1 region
of the hippocampus. The quantification and analysis of A11
Figure 5 A11 immunostaining in the hippocampus of 13- and 24-month-old mice
(A) The CA1 region of hippocampi from APP23 mice stained with the A11 antibody to visualize soluble oligomers. The images
represent the approximate average levels of A11 immunostaining in both young and old mice (1006). (B) The histogram represents
the percentage area of the hippocampi covered by A11-immunolabelled oligomers. n56 mice per group. Statistics by one-way
ANOVA and Tukey’s multiple comparison post-hoc tests. Note a significant effect of age (P,0.01 when 13-month-old APP23/wt are
compared with 24-month-old APP23/wt) and genotype (P,0.05 when 24-month-old APP23/wt are compared with 24-month-old
APP23/het). (C) Representative images of A11 immunoreactivity in the cortex of 13- and 24-month-old APP23 mice. (D) Histogram
representing the percentage area of the cortex covered by A11-immunolabelled oligomers. n56 mice per group. Note a significant
effect of age (P,0.05 when 13-month-old APP23/wt are compared with 24-month-old APP23/wt), but not of genotype (no
statistical significance when 24-month-old APP23/wt are compared with 24-month-old APP23/het). (E) Brain section from APP23/wt
co-stained with the A11 antibody and DAPI (10006, confocal microscopy). A11 immunostaining is located outside the nucleus but
mostly in the cell body layer of CA1. (F) Representative brain section from APP23/wt co-stained with the X-34 and A11 antibodies
(4006). A11 immunostaining is located outside fibrillar amyloid plaques.
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was a substantial and statistically significant difference
among the groups (P,0.001; Figure 5B). Post-hoc analysis
showed that A11 immunoreactivity within the CA1 signifi-
cantly increased with age (Figure 5B). For example, 24-
month-old APP23/wt mice had 4-fold more A11 staining than
13-month-old APP23/wt (0.8100¡0.2078 and 0.2049¡
0.06877 respectively, P,0.01). To determine the effect of
the genotype we first compared younger APP23/wt and
APP23/ko mice at 13 months of age. As shown in Figure 5(B),
A11 immunostaining in 13-month-old APP/ko mice was
slightly, but not significantly, increased compared with
APP23/wt mice (0.2049¡0.06877 compared with
0.2991¡0.1370, P.0.05). However, significantly more A11
immunostaining was observed in the CA1 of 24-month-old
APP23/het mice when compared with age-matched APP23/wt
mice (1.669¡0.1963 compared with 0.8100¡0.2078,
P,0.001). These results suggest that A11-positive oligomers
in the CA1 region of the hippocampus in the examined mice
depend on the Abca1 genotype and their amount increases
with aging.
In the cortex of 24-month-old APP23/wt and APP23/het
mice there was no significant difference in A11 immuno-
staining (Figure 5C). Similarly, there was no significant
difference in A11 immunostaining in the cortex of 13-
month-old APP23/wt and APP23/ko mice (Figure 5C).
However, there was significantly more A11 immunostaining
in 24-month-old APP23/wt mice when compared with 13-
month-old APP23/wt (Figures 5B and 5C; 1.53 compared with
0.73, P,0.05), suggesting an age-related increase in A11
immunostaining in the cortex.
To further determine the location of A11 immunostained
oligomers, we performed co-staining of brain sections from
24-month-old APP23/wt mice to label nuclei and senile
plaques. Brain sections co-stained with A11 and DAPI nuclear
stain showed A11 immunostaining surrounding, but situated
outside, the nucleus in both the cortex and hippocampus.
Interestingly, within the hippocampus, A11-immunostained
oligomers were located almost exclusively in the cell body
layer of the CA1 region (Figures 5E and 5F). Brain sections co-
stained with A11 antibody and X-34 showed A11 immuno-
staining located outside fibrillar plaque formations
(Figure 5F).
DISCUSSION
In the present paper, we describe novel findings that memory
deficits in 2-year-old APP23 mice depend on Abca1 gene
dosage and are likely to be mediated by the amount of Ab
oligomers deposited in the hippocampus. We used the MWM
to assess spatial learning and memory retention in age-
matched APP23/wt and APP23/het mice. When compared
with APP23/wt mice, APP23/het mice demonstrated impaired
learning during the acquisition phase, as well as impaired
memory retention during the probe trial. Importantly, we
found a significant difference in the level of soluble A11-
positive Ab oligomers which correlates negatively with the
cognitive performance. Furthermore, there was an unexpec-
ted region-specific redistribution of Ab oligomer structures,
predominantly in the CA1 of APP23/het mice. Thus the results
of the present study implicate Abca1 deficiency in the
development of behavioural deficits which are an important
aspect of AD pathogenesis. Taken together, the results
contribute to further understanding the significance of the
Abca1–ApoE axis in AD model mice, suggesting a role in the
development of cognitive impairments along with already
proven effects of these proteins on amyloid deposition and
clearance.
There are several possible explanations for the worse
memory performance of APP23/het compared with APP23/wt
mice in the MWM. First, the amount and possibly the
distribution of oligomeric Ab deposited in brain could be
responsible, although the precise mechanism by which
amyloid fibrils or soluble aggregates impair the cognition of
APP transgenic mice remains to be elucidated. Notably, Ab
can exist as monomers, low-molecular-mass oligomers such
as dimers, trimers, Ab*56, larger globular oligomers (ADDL,
amylospheroids, and globulomers), protofibrils, fibrils and
amyloid plaques (Lambert et al., 1998; Hoshi et al., 2003;
Kayed et al., 2003; Lesne et al., 2006; Chimon et al., 2007;
Shankar et al., 2008). However, it is not clear which of these
Ab assemblies is causative for the memory decline observed in
AD. Other evidence suggests that non-fibrillar assemblies of
Ab play a critical role in the pathogenesis of AD (Lambert et
al., 1998; Hoshi et al., 2003; Kayed et al., 2003; Lesne et al.,
2006; Chimon et al., 2007; Shankar et al., 2008). Studies from
transgenic AD models, and organotypic and cell culture
models have provided convincing support that soluble Ab can
be detrimental to many key neuronal activities. In the present
study, we found that there was an age-dependent increase in
the level of Ab*56 oligomer in APP23 mice, suggesting that
potentially it could be a marker for memory function in this
model, as in other APP transgenic mice (Lesne et al., 2006;
Billings et al., 2007). However, the level of Ab*56 oligomer
was unchanged in 24-month-old APP23/wt compared with
APP23/het mice. In contrast, our results demonstrate that the
increase of A11-positive Ab oligomers depends not only on
the age, but also on Abca1 genotype. As demonstrated in
Figure 4, in 24-month-old APP23/het mice the amount of
A11-positive Ab oligomers is increased 2-fold compared with
age-matched APP23/wt mice, and this increase correlated
negatively with their performance during the MWM probe
trial. Furthermore, there was a corresponding increase of A11
immunoreactivity in the CA1 region in the hippocampus of
those mice, which was strikingly different, compared with
what was observed in APP23/wt mice. As in other AD models
(Maezawa et al., 2008) we found A11 staining in the CA1 to
be mostly intracellular. This pattern of staining with deposits
comprising Ab accumulations in neurons, observed only in
Abca1, Ab oligomers and learning in APP23 mice
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73the CA1, but not in other regions, of the hippocampus, was
recently reported in human APOE4, but not in human APOE3,
targeted replacement (knock-in) mice. These characteristic
intracellular Ab42 aggregates, which were A11-positive and
likely to be Ab oligomeric structures, also corresponded to the
memory deficits in those mice (Belinson et al., 2008). In
addition, in brain sections from APP23 mice of all ages
examined in the present study and regardless of the Abca1
genotype, the extracellular staining with A11 antibody was
spatially segregated from the plaques, similar to human AD
brain (Kayed et al., 2003).
Insoluble Ab, amyloid plaques and plaque-associated
neuritic dystrophy have all been assigned a pathogenic role
with abundant evidence linking the extent of learning and
memory impairment as well as behavioural deficits to amyloid
burden and the amount of insoluble Ab in APP-expressing
mice. However, in a difference from oligomeric Ab we did not
find a correlation between the increased levels of insoluble
Ab40 and performance in MWM. Furthermore, there was no
statistically significant difference in the levels of insoluble Ab
and Thio-S-positive plaques between APP23/wt and APP23/
het groups.
Based on previous studies and the results of the present
study we propose that an increase of soluble oligomeric Ab in
specific brain areas, most prominently in the CA1 region of
the hippocampus, rather than the elevated amount of
insoluble Ab40 itself, contributes to the cognitive deteriora-
tion of aged APP23/het animals. At this point we can only
speculate about the reason why Ab oligomers are increased in
APP23/het mice. A potential reason may be the decreased
total amount of ApoE, which was significantly lower in
APP23/het compared with APP23/wt mice (Figure 2A). It has
been demonstrated that in Tg-SwDI mice complete absence
of ApoE increased the amount of soluble Ab oligomers in
brain parenchyma in spite of markedly decreasing depositions
of insoluble Ab and with no effect on total brain Ab (Miao et
al., 2005). Furthermore, binding of Ab to normally lipidated
ApoE and ApoA-I, which depends on functional and properly
expressed Abca1, could decrease the formation of Ab
aggregates, such as fibrils, protofibrils or globular oligomers.
For example, it was demonstrated that the ApoE effect on Ab
aggregation depends on its lipidation status, with lipid-rich
ApoE being more effective in decreasing Ab aggregation
(LaDu et al., 1994, 1995; Maezawa et al., 2004). In addition,
experiments with neuronal cell lines have shown that ApoA-I
b i n d i n gt oA b decreases its aggregation and toxicity
(Koldamova et al., 2001; Maezawa et al., 2004).
It is also possible that the difference in the performance of
APP23/wt and APP23/het mice could be linked to brain
lipoprotein metabolism and cholesterol transport within the
brain and between neurons and glia. In a series of elegant
studies, Pfrieger and colleagues showed that the ability of
CNS neurons to form synapses is limited by the availability of
cholesterol (Pfrieger and Barres, 1997; Mauch et al., 2001).
CNS neurons synthesize enough cholesterol to survive and
grow, but the formation of numerous mature synapses
demands additional amounts that must be provided by glia.
Synaptogenesis requires large amounts of cholesterol and
therefore depends on its delivery via ApoE-containing
lipoproteins (Pfrieger and Barres, 1997; Mauch et al., 2001).
The present study indicates that, in the brain of APP23/het
mice, there is less ApoE, which may lead to insufficient
amounts of cholesterol being delivered to surrounding axons
and therefore less efficient synaptogenesis. One possible
consequence of the less efficient synaptogenesis is a
behavioural deficit. Results from recently published studies
with LXR ligands confirm such a possibility: it has been shown
that application of synthetic LXR ligands (T0901317 and
GW3965) improves memory deficits in Tg2576 mice (Riddell
et al., 2007; Jiang et al., 2008). The main conclusion from
these studies is that LXR-dependent mechanisms in the brain,
most probably mediated through the established Abca1–ApoE
axis, are responsible for the beneficial effect of the ligands.
More importantly, these mechanisms could be amenable to
pharmacological modulation if proper LXR ligands become
available in the future.
In addition, the results of the present study suggest that
heterozygous Abca1 mice could be considered a valuable
model when overexpressing human genes related to AD types
of neurodegeneration, or with global disruption of genes
involved in neurological disorders known for perturbed
neuronal development or impaired synaptic plasticity. In
terms of their impaired cholesterol metabolism, heterozygous
Abca1 mice show an intermediate phenotype between
Abca1
wt and Abca1
2/2 (Koldamova et al., 2005a). The
beneficial effect of ABCA1
wt homozygosity in humans is
underscored by numerous studies demonstrating perturbed
cholesterol and lipoprotein homoeostasis in individuals hetero-
zygous for ABCA1 mutant alleles. Therefore Abca1 heterozyg-
ous mouse models (presumably ones that carry mutant,
clinically significant alleles), rather than mice completely
lacking Abca1 should be considered more relevant to study the
influence of perturbed brain cholesterol metabolism on
molecular pathogenesis and progression of different neuro-
degenerative disorders.
Lastly, although previous studies have examined the effect
of Abca1 on brain amyloid deposition and clearance in APP
transgenic mice (Hirsch-Reinshagen et al., 2005; Koldamova
et al., 2005a; Wahrle et al., 2005), to our knowledge our
present study is the first investigation addressing the role of
Abca1 on cognitive performance. Previous studies have
demonstrated that global deletion of Abca1 substantially
increases amyloid deposition in the brain parenchyma and
vasculature, possibly through facilitated Ab aggregation. In
addition, recent data suggest that properly lipidated brain
ApoE and ApoA-I lipoproteins are necessary for Ab degrada-
tion and clearance of amyloid deposits (Jiang et al., 2008;
Wahrle et al., 2008). Such findings present evidence for the
important regulatory function of Abca1 in brain cholesterol
homoeostasis and AD pathology, and provide a rationale for
behavioural studies, such as the present study, examining the
role of Abca1 in AD model animals.
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